Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil for brain side effects? study pulled before start

NCT ID NCT00621634

Symptom relief Sponsor: Université de Montréal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if high-dose DHA (an omega-3 fatty acid) could reduce involuntary movements in people with tardive dyskinesia, a side effect of long-term antipsychotic medication. It planned to enroll 40 adults aged 30-75 with schizophrenia and tardive dyskinesia, giving them DHA or placebo for 12 weeks. However, the study was withdrawn before any participants were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Feb 2008

An estimate. Start dates often move.

Finished

Feb 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients under long-term antipsychotic drug treatment, stable for at least 3 months before study entry; * presence of tardive dyskinesia following Schooler-Kane research criteria (mild intensity (2/4 points) in at least two body segments, or moderate intensity (3∕4 points) for at least one body segment); * patients capable to understand the goals and procedures of the study, and to provide informed consent; * women of childbearing age will be requested to use an effective contraceptive method throughout the study. Exclusion Criteria: * subjects with medical conditions susceptible to significantly increase the risk of adverse effects, or to interfere with the conduct of the study; in particular, those with coronary artery disease treated with clopidogrel, coagulation disorders, or hemorrhagic conditions; * those regularly taking anticoagulants or certain triglyceride-lowering agents; * those intolerant or allergic to fish, seafood, or any other substance contained in the study medication or matching placebo; * those who have abused illegal street drugs during the past year; * those unlikely to comply with the study requirements; * those who consume natural health products of marine or vegetable source, containing omega-3 essential fatty acids; * women who are pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tardive dyskinesia

Contacts and locations

Locations

  • Douglas Mental Health University Institute

    Montreal, Quebec, H4H 1R3, Canada

  • Notre-Dame Hospital/CHU Montreal

    Montreal, Quebec, H2L 4M1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.